Quality improvement cost-effectiveness will be combined with treatment cost-effectiveness according to the Mason model [ 62, 63].
Development of new peer or lay health-related lifestyle advisor (HRLA) roles is one response to the need to enhance public engagement in, and improve cost-effectiveness of, health improvement interventions.
The first stage involved two research projects which generated different types of relevant knowledge for service improvement: cost and effectiveness of service pathways and service-user experience of services and self-management.
There would be a further improvement in cost effectiveness if the proportion of households carrying out remediation when the measured radon exceeded the action level (to date around 20%266) could be increased (fig 3).
Although a direct comparison between the appraisal results and this study is not possible because of a different intervention and comparator, an improvement in cost effectiveness of 25%% could have implications on decision making at a threshold of £20,000 £30,000 per QALY, particularly in subgroups with minimally classic lesions and occult no classic lesions.
The evidence for concurrent improvement in efficiency, cost effectiveness or clinical effectiveness is inadequate or ambiguous.
This is largely attributable to advances in horizontal drilling and well stimulation technologies and improvements in their cost effectiveness.
Most improvements in overall cost effectiveness attained with a screening strategy are due to the reduction in live births with Down's syndrome.
Two large pragmatic cluster randomised trials [ 6, 7] with ambulatory primary care clinics as the unit of randomisation demonstrated clear impact improvements and acceptable cost effectiveness [ 8] due to a different in-service training approach (on-site, face-to-face team training by an outreach trainer), compared with usual off-site training.
Parker and McGirt described the concept of minimally clinically effective difference as the amount of improvement necessary to achieve cost effectiveness.
27 In light of our findings indicating no effect of screening on survival that is, improvement in cure rates these cost effectiveness results do not seem plausible.
